MAIA Biotechnology

IN THE PRESS

Press Releases

MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

March 31, 2026

·

6 min read

Press Releases

MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock

March 5, 2026

·

5 min read

Press Releases

MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock

March 3, 2026

·

5 min read

Press Releases

MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

March 3, 2026

·

5 min read

Press Releases

MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market

February 24, 2026

·

5 min read

Press Releases

MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum

January 21, 2026

·

7 min read

Press Releases

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

December 25, 2025

·

5 min read

Press Releases

MAIA Biotechnology Announces $1.51 Million Private Placement

December 17, 2025

·

4 min read

Press Releases

MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates

December 12, 2025

·

5 min read

Press Releases

MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer

December 12, 2025

·

6 min read

JOBS